Myelofibrosis Market is Projected to Grow Significantly by 2036 Owing to the Launch of Novel Disease-Modifying Therapies | DelveInsight

The market dynamics for Myelofibrosis are witnessing substantial growth driven by the increasing prevalence of the disease, rising adoption of JAK inhibitors, growing awareness of myeloproliferative neoplasms, and the development of innovative disease-modifying therapies. Additionally, the launch of emerging therapies such as XPOVIO (Karyopharm Therapeutics), RYTELO, Navtemadlin, Pelabresib (Novartis), INCA033989 (Incyte), Bomedemstat (Merck), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Myelofibrosis Market Insight, Epidemiology, and Market Forecast-2036." This comprehensive report provides an in-depth understanding of Myelofibrosis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Myelofibrosis Market

*
The Myelofibrosis market size in the 7MM is expected to grow significantly during the forecast period 2026-2036.

*
As per DelveInsight estimates, the total Myelofibrosis market in the 7MM was valued at nearly USD 2,600 million in 2025.

*
The United States accounted for the largest Myelofibrosis market size in 2025, at nearly USD 2,000 million among the 7MM.

*
Based on DelveInsight's assessment, the 7MM had approximately 56,200 prevalent cases of Myelofibrosis in 2025.

*
In the 7MM, the US accounted for the highest number of prevalent cases, contributing nearly 35% of the total patient population in 2025.

*
Primary Myelofibrosis accounted for a higher number of cases than secondary Myelofibrosis across the 7MM.

*
In Japan, there were approximately 9,300 cases of primary Myelofibrosis and 3,900 cases of secondary Myelofibrosis in 2025.

*
Currently, four JAK inhibitors are approved for the treatment of Myelofibrosis: JAKAFI/JAKAVI (ruxolitinib), INREBIC (fedratinib), VONJO (pacritinib), and OJJAARA/OMJJARA (momelotinib).

*
Leading companies developing Myelofibrosis therapies include Karyopharm Therapeutics, Geron, Novartis, Incyte, Merck, Kartos Therapeutics, Takeda/Keros Therapeutics, Syntara, Disc Medicine, and others.

*
Promising emerging therapies include XPOVIO (selinexor), RYTELO (imetelstat), Pelabresib, INCA033989, Navtemadlin, Bomedemstat, Elritercept, DISC-0974, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/myelofibrosis-mf-market [https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Myelofibrosis Market

Increasing Prevalence and Disease Burden:- The growing prevalence of Myelofibrosis, coupled with improved diagnostic capabilities and greater disease awareness, is contributing to increased treatment demand across the major markets.

Expanding Adoption of JAK Inhibitors: - JAK inhibitors have transformed the treatment landscape for intermediate- and high-risk Myelofibrosis patients. Approved therapies such as JAKAFI, INREBIC, VONJO, and OJJAARA continue to drive market growth by improving symptom burden and splenomegaly management.

Emergence of Disease-Modifying Therapies:- Several novel therapies targeting mechanisms beyond JAK inhibition, including telomerase inhibition, BET inhibition, MDM2 inhibition, calreticulin inhibition, and LSD1 inhibition, are advancing through clinical development and are expected to reshape the treatment paradigm.

Myelofibrosis Competitive Landscape:- The Myelofibrosis pipeline remains highly active, with several companies advancing innovative therapies designed to improve survival outcomes, reduce symptom burden, and potentially modify disease progression.

Leading pipeline candidates include XPOVIO (selinexor) by Karyopharm Therapeutics, RYTELO (imetelstat) by Geron, Pelabresib by Novartis, INCA033989 by Incyte, Navtemadlin by Kartos Therapeutics, Bomedemstat by Merck, Elritercept by Takeda/Keros Therapeutics, SNT-5505 by Syntara, and DISC-0974 by Disc Medicine.

These therapies target diverse mechanisms including selective inhibition of nuclear export, telomerase inhibition, BET inhibition, calreticulin inhibition, MDM2 inhibition, and LSD1 inhibition, aiming to address significant unmet needs in Myelofibrosis treatment.

Discover more about therapies set to grab major Myelofibrosis market share @ Myelofibrosis Treatment Landscape [https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Myelofibrosis Market

*
In January 2026, Cellenkos received Orphan Drug Designation (ODD) from the US FDA for CK0804 for the treatment of Myelofibrosis.

*
In October 2025, Novartis paused the development of INCB57643 in Phase II studies for Myelofibrosis in combination with JAKAFI due to safety concerns.

*
In July 2025, Bristol Myers Squibb announced that the Phase III INDEPENDENCE trial evaluating REBLOZYL in Myelofibrosis-associated anemia failed to meet its primary endpoint.

*
In June 2025, QIAGEN and Incyte announced a global collaboration to develop a diagnostic panel supporting investigational therapies including INCA033989.

*
According to Karyopharm Therapeutics, top-line data from the Phase III SENTRY trial evaluating XPOVIO plus ruxolitinib are expected in March 2026.

*
Geron expects interim analysis results from the Phase III IMpactMF trial of RYTELO in relapsed/refractory Myelofibrosis during the second half of 2026.

What is Myelofibrosis?

Myelofibrosis is a rare chronic myeloproliferative neoplasm characterized by abnormal bone marrow fibrosis, ineffective blood cell production, splenomegaly, constitutional symptoms, and progressive bone marrow failure. The disease exists as primary Myelofibrosis or secondary Myelofibrosis arising from polycythemia vera or essential thrombocythemia. Mutations in JAK2, CALR, MPL, and TET2 genes are associated with the majority of cases.

Myelofibrosis Epidemiology Segmentation

The Myelofibrosis epidemiology section provides insights into the historical and current patient pool and forecasted trends for the 7MM. The report offers epidemiological analysis for the study period 2022-2036 segmented into:

*
Total Prevalent Cases of Myelofibrosis

*
Type-specific Prevalent Cases of Myelofibrosis

*
Prevalent Cases Based on Risk Stratification

*
Age-specific Prevalent Cases of Myelofibrosis

*
Prevalent Cases Based on Molecular Alterations

*
Myelofibrosis Patients Based on Transplant Eligibility

Scope of the Myelofibrosis Market Report

*
Therapeutic Assessment: Myelofibrosis current marketed and emerging therapies

*
Myelofibrosis Market Dynamics: Key Market Forecast Assumptions and Market Outlook

*
Key Companies: Karyopharm Therapeutics, Geron, Novartis, Incyte, Merck, Kartos Therapeutics, Takeda/Keros Therapeutics, Syntara, Disc Medicine, and others

*
Key Therapies: JAKAFI/JAKAVI, INREBIC, VONJO, OJJAARA/OMJJARA, XPOVIO, RYTELO, Pelabresib, INCA033989, Navtemadlin, Bomedemstat, DISC-0974, Elritercept, and others

*
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

*
Unmet Needs, KOL Views, Analyst Views, Market Access and Reimbursement

To know more about Myelofibrosis companies working in the treatment market, visit @ Myelofibrosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myelofibrosis-market-is-projected-to-grow-significantly-by-2036-owing-to-the-launch-of-novel-diseasemodifying-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.